JANUVIA SITAGLIPTIN 25MG 28TABS

Description

Monotherapy: JANUVIA is indicated as a supplement to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Combination with metformin: JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin as initial treatment or when a single agent with diet and exercise do not provide sufficient glycemic control.

Combination with a sulfonylurea: JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a sulfonylurea when single agent treatment with diet and exercise does not provide sufficient glycemic control.

Combination with a PPAR agonist: JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a PPAR agonist (eg, thiazolidinediones) when single-agent treatment with diet and exercise, it does not provide sufficient blood glucose control.

Combination with metformin and a sulfonylurea: JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual treatment with these agents, with diet and exercise, does not provide sufficient control of blood glucose. blood glucose.

Combination with metformin and a PPAR agonist: JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a PPAR agonist (eg, thiazolidinedione) when dual treatment with these agents with diet and exercise do not provide sufficient glycemic control.

Combination with insulin: JANUVIA is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin (with or without metformin).